TNDM, US8753722037

Tandem Diabetes Care stock gains 2.36 percent before Q3 results

Published on 10/05/2026 at 18:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tandem Diabetes Care stock trades at USD 16.89 on Nasdaq on October 5, 2026. Q2 revenue reached USD 254.56 million while the GAAP loss narrowed year over year.

TNDM, US8753722037, Illustration mit AI erstellt.

Tandem Diabetes Care (ISIN US8753722037) stock was trading at USD 16.89 on Nasdaq at 12:39 p.m. ET on October 5, 2026, up 2.36 percent from the USD 16.50 prior close. The company plans to publish third quarter 2026 results on November 5, giving the recent move a clearly dated checkpoint, according to Business Wire on October 1, 2026.

November results set the next test

The November report will show whether Tandem can build on its second quarter operating improvement. For the quarter ended June 30, 2026, revenue reached USD 254.56 million, compared with USD 240.68 million a year earlier, while the GAAP net loss narrowed from USD 52.4 million to USD 21.17 million, according to Markets Insider in a report dated October 2, 2026.

The quarterly revenue comparison represents a 5.8 percent increase, while the smaller loss gives the November release two measurable operating benchmarks. The latest finance figures also show a Q2 operating loss of USD 13.792 million and diluted GAAP EPS of negative USD 0.31 for the period ended June 30, 2026.

Mobi expands the commercial test

Tandem's product expansion is another part of the upcoming earnings story. On September 28, 2026, Tandem Mobi became available in 12 countries outside the United States, including Germany, Italy, Spain, Switzerland and the United Kingdom, with orders and shipments starting in those markets, according to Tandem Diabetes Care.

The rollout gives the company a concrete international sales measure for the next report. Tandem's portfolio includes the Mobi system and the t:slim X2 pump, both using Control-IQ+ technology, according to the company's investor-relations page.

Consensus stays above the market price

Analyst views remain divided on how quickly the commercial expansion can translate into profit. RBC Capital analyst Kendall Au maintained a Buy rating and a USD 26.00 price target on October 1, 2026, according to Markets Insider.

MarketBeat lists a Hold consensus based on 23 analysts, with an average target of USD 29.13, a high target of USD 55.00 and a low target of USD 15.50. The average target lies 72.5 percent above the USD 16.89 Nasdaq price, placing execution and the November results at the center of the valuation debate.

Nasdaq price advances into October

TNDM was last at USD 16.89 on Nasdaq at 12:39 p.m. ET on October 5, 2026, up 2.36 percent on the session. The stock's 52-week range was USD 12.26 to USD 29.65, with market capitalization at USD 1.2 billion and volume at 419,008 shares.